Clinical and Molecular Pharmacology of Etomidate

Stuart A. Forman, M.D., Ph.D.*

**ABSTRACT**

This review focuses on the unique clinical and molecular pharmacologic features of etomidate. Among general anesthesia induction drugs, etomidate is the only imidazole, and it has the most favorable therapeutic index for single-bolus administration. It also produces a unique toxicity among anesthetic drugs: inhibition of adrenal steroid synthesis that far outlasts its hypnotic action and that may reduce survival of critically ill patients. The major molecular targets mediating etomidate effects in the central nervous system are specific γ-aminobutyric acid type A receptor subtypes. Amino acids forming etomidate binding sites have been identified in transmembrane domains of these proteins. Etomidate binding site structure models for the main enzyme mediating etomidate adrenotoxicity have also been developed. Based on this deepening understanding of molecular targets and actions, new etomidate derivatives are being developed. Based on this deepening understanding of molecular targets and actions, new etomidate derivatives are being investigated as potentially improved sedative– hypnotics for use as highly selective inhibitors of adrenal steroid synthesis.

* Associate Professor of Anaesthesia, Harvard Medical School, Boston, Massachusetts, and Associate Anesthetist, Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts.

Received from Massachusetts General Hospital, Boston, Massachusetts. Submitted for publication July 6, 2010. Accepted for publication September 17, 2010. Supported by grant PO1GM58448 from the National Institutes of Health (Bethesda, Maryland); and the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts. Massachusetts General Hospital has submitted patent applications for MOC etomidate, carboetomidate, and related analogs. The author and his laboratory, department, and institution could receive royalties relating to the development or sale of these drugs.

Address correspondence to Dr. Forman: Department of Anesthesia, Critical Care, and Pain Medicine, Jackson 444, Massachusetts General Hospital, 55 Fruit Street, Boston, Massachusetts 02114, saforman@partners.org. Information on purchasing reprints may be found at www.anesthesiology.org or on the masthead page at the beginning of this issue. ANESTHESIOLOGY's articles are made freely accessible to all readers, for personal use only, 6 months from the cover date of the issue.

Copyright © 2011, the American Society of Anesthesiologists, Inc. Lippincott Williams & Wilkins. Anesthesiology 2011; 114: 695–707

**ETOMIDATE** [R-1-(1-ethylphenyl)imidazole-5-ethyl ester] (fig. 1) is a unique drug used for induction of general anesthesia and sedation. The first report on etomidate was published in 1965 as one of several dozen aryl alkyl imidazolyl-carboxylate esters synthesized by Janssen Pharmaceuticals (a division of Ortho-McNeil-Janssen Pharmaceuticals, Titusville, NJ). Initially developed as antifungal agents, the potent hypnotic activity of several compounds was observed during animal testing; and several compounds, including etomidate, appeared significantly safer than barbiturates.

Etomidate contains a chiral carbon (fig. 1). Initial studies of racemic etomidate in rats demonstrated lethality at approximately 12 times its effective hypnotic dose (median lethal dose/ED$_{50}$, approximately 12) compared with barbiturates with median lethal dose/ED$_{50}$ ratios (therapeutic indexes) of 3–5. Subsequent studies found that the isolated $R$-enantiomer of etomidate has 10–20-fold greater hypnotic potency than $S$-etomidate. The median lethal dose/ED$_{50}$ ratio for $R$-etomidate is 26 in rats, significantly higher than therapeutic indexes for other general anesthetics (table 1). Preclinical experiments in mammals also demonstrated that etomidate injection was associated with minimal hemodynamic changes or respiratory depression, features that were presumed to result in its unusually favorable safety profile.

Etomidate was introduced into clinical practice in 1972, and initial reports of its use in humans emerged in the clinical literature soon afterward. Academic publications focusing on etomidate increased steadily until 1983, when the number of reports rapidly doubled after discovery of its adrenal toxicity (fig. 2). Subsequently, the number of yearly published articles focusing on etomidate diminished (apparently in parallel with its use in operating rooms), but this rate has resurfaced in the past decade. Renewed interest in etomidate parallels its widening use during intubations in emergency departments and intensive care units, and new concerns exist about the impact of etomidate-induced adrenal toxicity in critically ill patients. The recent increase in publications on etomidate also reflects scientific progress in understanding this drug’s molecular pharmacologic features.
Clinical Pharmacology

Formulation and Dosing

Etomidate formulations for clinical use contain the purified \( R^+ \)-enantiomer. Etomidate has a \( pK_a \) of 4.2 and is hydrophobic at physiologic pH. To increase solubility, it is formulated as a 0.2% solution either in 35% propylene glycol (Amidate; Hospira, Inc, Lake Forest, IL) or lipid emulsion (Etomidate-Lipuro; B. Braun, Melsungen, Germany). For formulations in cyclodextrins have also been developed. Early clinical studies determined that intravenous bolus doses of 0.2–0.4 mg/kg provided hypnosis for 5–10 min. After a bolus, maintenance of general anesthesia can be achieved by continuous infusion of etomidate at 30–100 \( \mu g \cdot kg^{-1} \cdot min^{-1} \). Oral transmucosal etomidate has been used to induce sedation, and rectal administration has been used to induce general anesthesia in pediatric patients.

Systemic Effects

Etomidate does not inhibit sympathetic tone or myocardial function, and typical anesthetic induction doses produce minimal blood pressure and heart rate changes in patients, including those with valvular or ischemic heart disease. For the same reason, etomidate does not block sympathetic responses to laryngoscopy and intubation; these responses are often blunted by premedication with opioids. Etomidate produces less apnea than barbiturates or propofol, no histamine release, and rare allergic reactions. Because of its remarkably benign hemodynamic effects, etomidate has proved useful for general anesthetic induction in patients undergoing cardiac surgery and in those with poor cardiac function.

Etomidate also provides advantages for induction of anesthesia in the setting of hemorrhagic shock. In a pig model of hemorrhagic shock, the pharmacodynamics and pharmacokinetics of etomidate are minimally altered, in contrast to other anesthetic drugs. As a result of its favorable profile for anesthetic induction in a variety of critically ill patients, etomidate has been adopted by many emergency medicine physicians as the hypnotic drug of choice for rapid-sequence induction and intubation.

Hepatic blood flow is modestly reduced after induction of general anesthesia with etomidate, but this has minimal impact on pharmacokinetics and metabolism of anesthetic agents. Cerebral blood flow is reduced, along with cerebral metabolic rate and intracranial pressure, whereas cerebral perfusion pressure is maintained or increased during etomidate-induced anesthesia. Electroencephalographic changes during hypnosis with etomidate are similar to those seen with barbiturates. Bispectral index monitor values decrease after etomidate bolus administration and return to baseline during recovery of consciousness. During brief etomidate infusions, bispectral index values correlate well with sedation scores. Etomidate increases latency and decreases amplitude of auditory evoked potentials.

**Table 1. Acute Toxicity Ratios of Intravenous Anesthetic Induction Drugs**

<table>
<thead>
<tr>
<th>Anesthetic Induction Drug</th>
<th>Acute Toxicity Ratio, LD50/ED50*</th>
</tr>
</thead>
<tbody>
<tr>
<td>( R^+ )-etomidate</td>
<td>26(^5)</td>
</tr>
<tr>
<td>Althesin (alphaxalone/alphadolone)</td>
<td>17.3(^{158})</td>
</tr>
<tr>
<td>Ketamine (racemic)(\dagger)</td>
<td>6.3(^{159})</td>
</tr>
<tr>
<td>Methohexital</td>
<td>4.8-9.5(^{5,158})</td>
</tr>
<tr>
<td>Thiopental</td>
<td>3.6-4.6(^{158,160})</td>
</tr>
<tr>
<td>Pentobarbital</td>
<td>3.4(^{160})</td>
</tr>
<tr>
<td>Propofol</td>
<td>3.4(^{158})</td>
</tr>
</tbody>
</table>

Data are from therapeutic index studies in mice and rats using intravenous injection. The therapeutic index of \( R^+ \)-ketamine is 10, whereas that of the \(-\)-enantiomer is 4.0. ED50 = dose that is pharmacologically effective to 50% of the experimental population; LD50 = dose resulting in 50% mortality within 24 h.
Anesthesiology 2011; 114:695–707

Stuart A. Forman

EDUCATION

Fig. 3. Single intravenous bolus pharmacokinetics of etomidate. The etomidate plasma concentration after a single intravenous bolus (3 mg/kg) is depicted on a semilogarithmic plot with the early decline period expanded. This concentration versus time profile is based on pharmacokinetic parameters determined by Van Hamme et al.,30 showing three distinct decline phases with half-times of 2 min, 21 min, and 3.9 h. Colored dashed lines indicate approximate threshold etomidate plasma concentrations associated with hypnosis (blue line at 200 ng/ml) and adrenocortical suppression (green line at 8 ng/ml). Together, these data illustrate why the duration of hypnosis (approximately 8 min) is much shorter than the duration of adrenocortical suppression (approximately 8 h) after a single etomidate dose.

Pharmacokinetics and Metabolism

In healthy patients, etomidate is approximately 75% protein bound.42 Etomidate is characterized by a large central volume of distribution, 4.5 l/kg, and a large peripheral volume of distribution, 74.9 l/kg, because of its high solubility in fat.30,37,43 The single-bolus pharmacokinetic profile of plasma etomidate concentration is described by a three-compartment model (fig. 3).30 The fast, intermediate, and slow declines in plasma etomidate are thought to correspond to distribution into highly perfused tissues, redistribution into peripheral tissues (mostly muscle), and terminal metabolism, respectively. The hypnotic effect of an intravenous bolus of 3 mg/kg etomidate terminates as redistribution into the peripheral compartment starts to dominate the plasma concentration profile. Etomidate metabolism in laboratory animals and humans depends on hepatic esterase activity, which hydrolyzes the drug to a carboxylic acid and an ethereal-leaving group.44 The carboxylate metabolite is excreted mostly in urine and to a lesser degree in bile. Total plasma clearance is 15–20 ml·kg⁻¹·min⁻¹, and the terminal metabolic half-life of etomidate in humans ranges from 2 to 5 h. Elderly or ill patients often require decreased etomidate doses because of reduced protein binding and reduced clearance.42,45,46

The pharmacokinetic parameters for etomidate indicate its suitability for use as a continuous infusion, with a context-sensitive half-time shorter than that of propofol.47 Prolonged etomidate infusion for anesthesia and sedation was practiced during the first decade of clinical availability.32,48–52 Other considerations (adrenal toxicity) preclude this application. (The Adrenal Toxicity, Sepsis, and Exogenous Steroids section provides further details.)

Adverse Effects

Several unfavorable effects associated with etomidate were noted in early studies, including pain on injection and myoclonic movements during induction of general anesthesia.53–55 Pain on injection was worse with etomidate in aqueous solutions compared with the formulation in 35% propylene glycol.56 Formulation into medium chain-length lipids or cyclodextrins appears to decrease the incidence of injection pain and hemolysis further.57 The incidence of myoclonus increases with etomidate dose and can be attenuated by split-dose induction58 or premedication with benzodiazepines,59 thiopental, dexmedetomidine,60 and/or opioids.61,62

Postoperative nausea and vomiting are cited as frequent adverse effects of etomidate, but few studies have formally compared postoperative nausea and vomiting after etomidate versus other agents used for induction of general anesthesia. Early investigators reported that the incidence of postoperative nausea and vomiting after induction with etomidate is approximately 40%,50,55 comparable with that after barbiturates,43,56 and higher than that after propofol.63 More recently, the reported incidence of nausea after induction with etomidate in lipid emulsion was similar to that associated with propofol,64,65 whereas the incidence of vomiting was higher with etomidate.65

Adrenal Toxicity, Sepsis, and Exogenous Steroids

Adrenal cortical inhibition by etomidate has received much attention and significantly limits its use as both an anesthetic and a sedative. Nevertheless, the effect of etomidate on clinical outcomes has never been carefully studied in a large population of surgical or intensive care patients.

In 1983, a decade after its introduction into clinical use, Ledingham and Watt66 reported retrospective data showing increased mortality among intensive care patients receiving prolonged etomidate infusions for sedation compared with patients receiving benzodiazepines (69% vs. 25%).67 Soon afterward, McKee and Finlay68 reported that cortisol replacement therapy could reduce the mortality in a similar group of critically ill patients receiving etomidate infusions. At that time, there was emerging preclinical evidence that etomidate suppressed adrenocortical function in rats,69 and clinical investigators70,71 rapidly confirmed this toxicity in patients. Etomidate suppressed normal cortisol and aldosterone increases after surgery and adrenal responses to corticotrophin. Adrenal suppression lasted 6–8 h in patients after a single-induction dose of etomidate72,73 and more than 24 h after etomidate infusion.74
The clinical community reacted to revelations about adrenal toxicity by ceasing the use of etomidate for long-term infusions. Some editorials recommended halting its use altogether, whereas others suggested that etomidate had value as a single-dose induction drug for selected patients. The drug package insert was amended to state that etomidate use is approved for induction of general anesthesia and anesthetic maintenance for short operative procedures. It specifically warns against administration by prolonged infusion.

Subsequent research showed that etomidate is far more potent as an inhibitor of steroid synthesis than as a sedative-hypnotic agent. Etomidate plasma concentrations associated with hypnosis in patients are higher than 200 ng/ml (1 μM), whereas concentrations less than 10 ng/ml are associated with adrenal cortical suppression. The in vitro IC₅₀ for etomidate inhibition of cortisol synthesis in cultured adrenal cells is 1 nM, which closely matches the apparent dissociation constant for etomidate binding to membranes of these cells. Together, the disparate etomidate concentration dependence values for hypnosis versus adrenotoxicity and multiphase pharmacokinetics account for the dramatic difference in the durations of these two actions after a single intravenous bolus (fig. 3).

Recently, concern about etomidate-induced adrenal toxicity in critically ill patients and the use of corticosteroids to treat this effect has reemerged. Exposure to single-dose etomidate was a confounding variable in a large multicenter trial evaluating the use of supplemental corticosteroids in septic patients with and without adrenal insufficiency. Enrollment in this study was from September 1995 to March 1999; in July 1996, inclusion criteria were altered to exclude patients who had received etomidate within 6 h. At that point, 72 enrollees had received etomidate, and 68 of these individuals were nonresponders to corticosteroids. Thus, at least 30% of the nonresponders in this study (229 in total) had received etomidate; it is likely that additional patients received etomidate between 6 and 24 h before enrollment. In a 500-patient follow-up study of low-dose corticosteroid therapy of septic shock (CORTICUS), etomidate was administered to 20% of patients before enrollment and 8% of patients after enrollment. Although etomidate was given on average 14 h before testing for adrenal insufficiency, it was associated with a 60% nonresponse rate to corticosteroids, significantly higher than that of enrollees who did not receive etomidate. Similar results have been reported by others. The CORTICUS study concluded that supplemental steroids did not improve the long-term outcome of septic shock patients with adrenal insufficiency. Retrospective analyses of the CORTICUS cohort suggest that patients receiving etomidate before enrollment had a 28-day mortality significantly higher than other patients in the trial and that steroids provided no benefit to those who received etomidate.

Other studies of patients with sepsis and trauma have examined the duration of adrenal insufficiency after single-dose etomidate and its effect on outcomes. In this population, the duration of adrenal suppression after a single dose of etomidate is longer than 24 h and may last up to 72 h. However, the impact of single-dose etomidate on outcomes in critically ill patients remains unclear. Hildreth et al. reported that trauma patients randomized to intubation using etomidate had longer hospital and intensive care unit lengths of stay than a group intubated using fentanyl and midazolam. In contrast to these and the CORTICUS study results, a nonrandomized study by Tekwani et al. found no difference in mortality among septic patients who received etomidate for intubation in the emergency department versus those who received other agents. Ray and McKeown also found no evidence of excess mortality associated with etomidate in a retrospective study. A recent randomized controlled trial comparing etomidate with ketamine for intubation of critically ill, mostly nonseptic, patients also found no difference in mortality. Clearly, large well-designed trials are needed to define the clinical impact of single-dose etomidate in critically ill patients. Meanwhile, a vigorous debate about the use of etomidate for intubation of these patients continues.

**Molecular Pharmacologic Features**

There are fewer clinical studies focusing on etomidate than on either propofol or isoflurane, yet the molecular pharmacologic features of etomidate are understood far better than other intravenous or inhaled general anesthetics. Etomidate appears to produce hypnosis, amnesia, and inhibition of nociceptive responses, almost exclusively via actions at one class of neuronal ion channels (i.e., γ-aminobutyric acid type A receptors [GABAₐ receptors]). Molecular targets mediating adrenal steroid inhibition and pain on injection have also been identified.

**GABAₐ Receptors: Mediators of Etomidate Anesthesia**

Soon after etomidate became available for clinical use, it was noted to produce effects similar to the endogenous neurotransmitter GABA in the nervous system. Indeed, it is firmly established that the molecular targets underlying the anesthetic actions of etomidate are GABAₐ receptors, which are the major inhibitory neurotransmitter receptors in mammalian brains. GABAₐ receptors are neurotransmitter-activated ion channels that selectively conduct chloride ions. Under normal conditions, their activation stabilizes neuronal membrane voltage near the chloride Nernst potential of −70 mV. GABAₐ receptors are members of the superfamily of Cys loop ligand-gated ion channels that includes nicotinic acetylcholine receptors from muscle and nerve, glycine receptors, and serotonin type 3A receptors. All of these receptors are structurally similar and are formed from five polypeptide subunits surrounding an ion-conductive transmembrane channel. All Cys loop receptor subunits consist of a large amino-terminal extracellular domain, four...
hydrophobic transmembrane domains (M1 through M4), and a large intracellular domain between M3 and M4. Structural models of GABA<sub>A</sub> receptors (fig. 4A–C) are based on high-resolution studies of crystallized acetylcholine-binding protein from snail synapses, homologous to extracellular domains,<sup>99</sup> Torpedo nicotinic acetylcholine receptors,<sup>100</sup> and crystallized pentameric prokaryotic channels.<sup>101-103</sup>

Eighteen distinct GABA<sub>A</sub> receptor subunits are encoded in the human genome,<sup>104</sup> but only approximately a dozen subunit combinations form neuronal channels. Most of these consist of two α subunits, two β subunits, and one γ subunit arranged γ-β-α-β-α counterclockwise when viewed from the extracellular space.<sup>105</sup> Heterologously expressed receptors containing α1, β2, and γ2 subunits display GABA sensitivity, drug sensitivity, and open-closed transition rates similar to synaptic GABA<sub>A</sub> receptors in the brain.<sup>106</sup> Synaptic GABA concentrations are thought to briefly reach several millimolar and to decay within milliseconds because of uptake via GABA transporters. Postsynaptic GABA<sub>A</sub> receptor channels open within a millisecond, generating an inhibitory postsynaptic current, which deactivates over tens of milliseconds, far longer than GABA remains in the synapse.<sup>107</sup> During an inhibitory postsynaptic current, action potential generation is impaired in the postsynaptic neuron; therefore, current deactivation is thought to be a factor in regulating the frequency response of neuronal circuits.<sup>108,109</sup> Some GABA<sub>A</sub> receptors, formed from α and β subunits in combination with δ or ε subunits, are expressed on neuronal cell bodies and axons.<sup>110</sup> These extrasynaptic receptors produce small tonic chloride “leak” currents in response to low micromolar concentrations of GABA in the extrasynaptic space.<sup>111,112</sup>

**Etomidate Actions at GABA<sub>A</sub> Receptors**

Two effects on GABA<sub>A</sub> receptors, produced by different concentrations of etomidate, have been described. At concentrations associated with clinical doses, etomidate positively modulates GABA<sub>A</sub> receptor activation by agonists.<sup>98</sup> In other words, when etomidate is present, GABA<sub>A</sub> receptors are activated by concentrations of GABA lower than required under normal conditions.<sup>2,113,114</sup> Clinical concentrations of etomidate also slow the inhibitory postsynaptic current decay mediated by syn-
aptic GABA<sub>A</sub> receptors, promoting long-lasting postsynaptic inhibition and reducing the frequency response of neuronal circuits. Enhanced activation of extrasynaptic receptors is also observed at clinical etomidate concentrations, increasing the tonic inhibitory “leak” current and reducing neuronal excitability. Yang and Uchida<sup>115</sup> noted that etomidate effects on tonic currents mediated by extrasynaptic GABA<sub>A</sub> receptors may be more important than effects on synaptic currents. Etomidate at supraclinical concentrations also directly activates synaptic GABA<sub>A</sub> receptor channels in the absence of GABA, an action variously termed direct activation, GABA-mimetic activity, or allosteric agonism.<sup>2,114,115,117</sup>

Both positive modulation of GABA-mediated activity and direct activation of GABA<sub>A</sub> receptors display parallel dependences on drug and receptor structures. For both etomidate actions, stereoselectivity for the (R)<sup>+</sup>-enantiomer is of the same magnitude (10- to 20-fold) seen in animal studies of hypnotic and anxiolytic activity.<sup>2,114,118,119</sup> Both etomidate actions also show similar dependence on GABA<sub>A</sub> receptor subunit makeup. Receptors containing β2 and/or β3 subunits are modulated and activated by etomidate, whereas those containing β1 are much less sensitive to both etomidate actions.<sup>113,117,120</sup> Etomidate sensitivity is also affected by the presence of a γ subunit<sup>113</sup> and weakly by the α subtype.<sup>117</sup>

These parallels suggest that a single class of etomidate sites on GABA<sub>A</sub> receptors mediates both modulation of GABA activation and direct activation. Indeed, both of these effects in α1β2γ2 δ<sub>L</sub> receptors can be quantitatively modeled with an equilibrium Monod–Wyman–Changeux allosteric agonist mechanism, by which etomidate binding to its sites is determined by whether the receptor is in one of two canonical states: open versus closed (fig. 5).<sup>114,119</sup> In essence, etomidate binds weakly (K<sub>E</sub>, approximately 35 μM) to closed receptors but tightly (K<sub>E</sub><sup>*</sup>, approximately 0.27 μM) to open receptors; therefore, the drug stabilizes open states whether GABA is bound or not bound. This class of model was optimal with two equivalent etomidate sites.

**Mutations That Alter Etomidate Sensitivity of GABA<sub>A</sub> Receptors**

A β subunit region containing the M2 domain influences the differential etomidate sensitivity of GABA<sub>A</sub> receptors containing β1 versus β2 subunits.<sup>121</sup> The only amino acid in M2 that differs between β1 and β2 is at position 265 of the mature protein. B265 is a serine (S) in β1 and an asparagine (N) in β2 and β3. A point mutation replacing β1S265 with N (β1S265N) increases etomidate sensitivity, whereas replacing β2 or β3N265 with S (β2/3N265S) dramatically reduces etomidate sensitivity.<sup>121</sup> Similarly, an anesthetic-insensitive mutant *Drosophila melanogaster* (fruit fly) line contains a methionine (M) at the homologous amino acid in M2, instead of the N found in the wild type. A mutation from N265 to M in the β2 or β3 subunit of mammalian GABA<sub>A</sub> receptors also confers insensitivity to etomidate.<sup>122-124</sup> Mutations at β2N265 produce parallel changes in etomidate modulation of GABA-activated receptor-mediated currents and direct activation of channels. Quantitative electrophysiologic analysis of GABA<sub>A</sub> receptors containing both β2N265S and β2N265M mutations show little impact on basal or GABA-mediated activation and different degrees of reduced etomidate sensitivity.<sup>125</sup> The β2N265M mutation totally eliminates etomidate sensitivity, whereas the β2N265S mutation reduces etomidate-induced shifts in GABA EC<sub>50</sub> (EC<sub>50</sub> ratio) more than 8-fold relative to the wild type (table 2).

All GABA<sub>A</sub> receptor β subunits contain a methionine at position 286 in their M3 domains, and βM286 mutations also influence etomidate sensitivity. The βM286W mutation eliminates etomidate modulation of receptors, whereas the homologous α2A91W mutation has no effect on etomidate actions.<sup>123,124,126</sup> Quantitative electrophysiologic analysis demonstrates that GABA<sub>A</sub> receptors containing the β2M286W mutation display both enhanced sensitivity to GABA and spontaneous activity, effects that mimic the actions of etomidate on wild-type channels (table 2).<sup>127</sup>

**Etomidate Anesthesia in Transgenic Animals**

Mutations at β2N265 and β3N265 have been incorporated into transgenic “knock-in” mice to test the role of these subunits in anesthetic actions. Jurd et al.<sup>128</sup> reported that β3N265M knock-in animals have grossly normal morphological and behavioral phenotypes but are resistant to both loss of righting
reflexes and antinociceptive (immobilizing) actions of etomidate and propofol at doses higher than those affecting 100% of wild-type animals. Reynolds et al. developed β2N265S knock-in mice and reported that they also have normal morphological features and behavior, including sleep and electroencephalographic activity. The β2N265S knock-in mice show normal sensitivity to etomidate for loss of righting reflexes and antinociceptive actions, but these mice are resistant to sedative and hypothermic actions of etomidate. Etomidate enhancement of tonic currents associated with extrasynaptic receptors is lost in neurons from β2N265S transgenic mice. Further evidence implicating extrasynaptic receptors is lost in neurons from β2N265S transgenic mice. The left-shift ratio is a measure of etomidate modulation of GABA responses. It is calculated as the ratio of GABA EC50 values in the absence of etomidate to that in the presence of 3.2 μM etomidate. A large ratio indicates sensitivity to etomidate modulation, whereas a ratio of 1.0 or less indicates no positive modulation.

CCTL = control; ETO = etomidate.

### Table 2. GABAA Receptor Mutant Effects on GABA and Etomidate Sensitivity*

<table>
<thead>
<tr>
<th>Receptor</th>
<th>Spontaneous Activation†</th>
<th>GABA EC50 (μM)‡</th>
<th>GABA Efficacy§</th>
<th>Etomidate EC50 (μM)‡</th>
<th>Etomidate Efficacy§</th>
<th>Left-shift Ratio (CNTL/ETO)†</th>
</tr>
</thead>
<tbody>
<tr>
<td>α1β2γ2L</td>
<td>&lt;0.001</td>
<td>26</td>
<td>0.9</td>
<td>36</td>
<td>0.4</td>
<td>20</td>
</tr>
<tr>
<td>α1M236Wβ2γ2L</td>
<td>0.16</td>
<td>2.0</td>
<td>0.99</td>
<td>12</td>
<td>0.97</td>
<td>1.7</td>
</tr>
<tr>
<td>α1β2M286Wγ2L</td>
<td>0.04</td>
<td>6.6</td>
<td>1.0</td>
<td>NA</td>
<td>&lt;0.001</td>
<td>1.1</td>
</tr>
<tr>
<td>α1β2N265Sγ2L</td>
<td>&lt;0.001</td>
<td>27</td>
<td>0.93</td>
<td>78</td>
<td>0.03</td>
<td>2.3</td>
</tr>
<tr>
<td>α1β2N265Mγ2L</td>
<td>&lt;0.001</td>
<td>32</td>
<td>0.84</td>
<td>NA</td>
<td>&lt;0.001</td>
<td>0.95</td>
</tr>
</tbody>
</table>

* All functional effects are estimated from voltage-clamp electrophysiological experiments on receptors expressed in Xenopus oocytes. † Spontaneous activation is a measure of the propensity of channels to open in the absence of agonist and other ligands. It is estimated using a potent channel blocker (picrotoxin) that inhibits the spontaneously active receptors. GABA's efficacy is an estimate of the fraction of maximum GABA current elicited by high GABA concentrations. We assume that the combination of high GABA plus allosteric enhancer activates all receptors. Etomidate's efficacy is the maximum current elicited by etomidate, normalized to the maximum current elicited by GABA. ‡ GABA EC50 is defined similarly for etomidate's direct activating (agonist) activity. § GABA's efficacy is the maximum current elicited by etomidate, normalized to the maximum current elicited by GABA.

More evidence that αM236 and βM286 are involved in etomidate binding comes from recent molecular studies of mutations at these residues. GABAA receptors with tryptophan mutations at either α1M236 or β2M286 display functional characteristics that mimic the reversible effects of etomidate on wild-type receptors. Both α1M236W and β2M286W also reduce receptor sensitivity to etomidate, perhaps because the large tryptophan side chains occupy the space where etomidate binds. Cysteine mutations have been used to introduce free sulphydryls at α1M236 and β2M286, which are accessible to modification by selective reagents. Sulphydryl modification of α1M236C or β2M286C is blocked by etomidate (Deirdre Stewart, Ph.D., Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston; unpublished research findings; April 1, 2010), confirming that the drug binds close to both residues. The hypothesis that etomidate binds between transmembrane helices on two adjacent GABAA receptor subunits differs from previous proposals that anesthetics bind within a single subunit. Recently, Bali et al. provided further evidence that αM236 and βM286 residues of GABAA receptors are on nearby helical domains and oriented toward interface clefs between subunits. Their experiments showed that β2M286C forms inter-subunit cross-linking di-
sulfide bonds with cysteines substituted at two α subunit M1 domain loci on the same helical face as α1M236.

**Etomidate Interactions With Adrenal Steroidogenesis Enzymes**

During etomidate infusion, plasma concentrations of cortisol, cortisone, and aldosterone decrease, whereas those of 11-deoxycorticosterone, 11-deoxycortisol, progesterone, and 17-hydroxyprogesterone increase. These clinical results, and related in vitro studies, indicate that etomidate inhibits adrenal steroid synthesis primarily by blocking the activity of CYP11B1, also known as 11β-hydroxylase or P450c11. This mitochondrial cytochrome enzyme converts 11-deoxycortisol to cortisol and 11-deoxycorticosterone to corticosterone and is 95% homologous to the CYP11B2 (aldolase) enzyme in the pathway leading to aldosterone.141

The imidazole ring of etomidate is likely to be a major determinant of its binding to adrenal cytochrome enzymes. Many other imidazole compounds inhibit CYP11B enzymes, and a variety of crystal structure studies confirm that imidazole nitrogens coordinate (form dipolar bonds with) heme irons located at the active sites of prokaryotic and eukaryotic cytochromes. High-efficiency in vitro production of purified human CYP11B1 has recently been reported, and high-resolution structural data for the molecule may be available in the near future. Homology models based on crystal structures of related enzymes have been developed and used for in silico ligand etomidate docking studies (fig. 6).147

**Adrenergic Receptors and Cardiovascular Stability With Etomidate**

α-2 Adrenergic receptors are activated by etomidate, but this action is unrelated to its hypnotic effects in mice. However, the transient hypertension produced by etomidate in wild-type mice is absent in knockout mice lacking either α2B or α2A adrenergic receptor subtypes. This result indicates that α2 adrenergic receptors may contribute to the hemodynamic effects of etomidate.

Etomidate’s remarkably benign cardiovascular and pulmonary effects are also likely the result of its selectivity for a few molecular targets. In comparison, clinically relevant concentrations of barbiturates, propofol, and volatile anesthetics modulate a broader array of GABAA receptor subtypes together with multiple other etomidate-insensitive ion channels found in both neurons and cardiovascular structures.149

**Channels That Mediate Etomidate Injection Pain**

Transient receptor potential type A1 cation channels are involved in inflammation and pain sensation. Like propofol and other general anesthetics, etomidate at high concentrations activates transient receptor potential type A1 channels, a mechanism that may underlie pain during injection.150

**New Drugs Based on Etomidate**

**Selective Adrenal Steroid Inhibitors**

Because of its unequalled potency as an inhibitor of cortisol and aldosterone synthesis, etomidate derivatives have been explored as selective biomarkers and inhibitors for diseases associated with excess adrenocortical activity. Positron-emitting derivatives of etomidate have been developed for localization of adrenal tumors, and infusion of etomidate is gaining popularity as a short-term treatment for poorly controlled Cushing’s disease. Subhypnotic doses of etomidate effectively reduce the high systemic cortisol and aldosterone concentrations associated with this disease, with mild sedation as an adverse effect. In addition to inhibiting steroid synthesis, etomidate inhibits proliferation of adrenal cortical cells, making it particularly useful in the treatment of metastatic adrenocortical tumors. In a recent report on several dozen synthetic etomidate derivatives, none demonstrated greater potency than etomidate for inhibition of cortisol synthesis by cultured adrenal cells. Several of these compounds show high potency for CYP11B binding but weak interactions with GABA_A receptors, suggesting that treatment for excess cortisol or aldosterone synthesis may be achieved without adverse sedative effects.

**Novel Anesthetic Agents**

Recent research has also aimed at modifying etomidate to improve its clinical utility as an anesthetic and sedative. Two molecular strategies have been described to maintain the favorable clinical features of etomidate while reducing the ac-
bolus administration, no adrenal suppression is found, for nearly an hour. Thirty minutes after MOC etomidate potent bolus of etomidate produced loss of righting reflexes produced anesthesia lasting only a few minutes, whereas an equi-

methyl ester linkage (fig. 7A). MOC etomidate modulates GABA receptors with a potency near that of etomidate but is rapidly (with a half-life of a few minutes) metabolized by nonspecific esterase enzymes in blood and tissue and converted to a carboxylic acid metabolite. The MOC etomidate metabolite is inactive as both an anesthetic and an inhibitor of adrenal steroid synthesis (Douglas Raines, M.D., Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital; oral communication; April, 2010). In rats, MOC etomidate bolus administration produced anesthesia lasting only a few minutes, whereas an equivalent bolus of etomidate produced loss of righting reflexes for nearly an hour. Thirty minutes after MOC etomidate bolus administration, no adrenal suppression is found, whereas significant adrenal suppression is associated with etomidate bolus administration. MOC etomidate is in preclinical development. Its potential use includes anesthesia induction and maintenance for up to several hours. Adrenal suppression may be present during anesthesia with MOC etomidate, but adrenal function is predicted to recover rapidly after cessation of drug infusion.

Carboetomidate is an etomidate “look-alike” drug that contains a five-membered pyrrole ring instead of an imidazole (fig. 7B).157 The loss of the free imidazole nitrogen eliminates coordination interactions with heme irons, reducing adrenal suppression potency by three orders of magnitude (IC₅₀ approximately 1 μM [vs. etomidate IC₅₀, 1 nM]), based on adrenal cell cortisol synthesis assays. Carboetomidate retains the ability to modulate and directly activate GABA receptors and is a potent sedative–hypnotic with systemic effects and a duration of action similar to that of etomidate in laboratory animals.

The following individuals are thanked for contributing illustrations and valuable feedback on the manuscript: Keith W. Miller, D.Phil., Professor of Anesthesiology; Douglas Raines, M.D., Associate Professor of Anesthesiology; Joseph Cotten, M.D., Ph.D., Assistant Professor of Anesthesiology; Shunmugasundararaj Sivananthaperuma, Ph.D., Research Associate; all of the Department of Anesthesia, Critical Care, and Pain Medicine, Massachusetts General Hospital, Boston, Massachusetts; and David Chiara, M.D., Ph.D., Senior Research Associate, Department of Neurobiology, Harvard Medical School, Boston, Massachusetts.

References


Clinical and Molecular Pharmacology of Etomidate


30. Longerheide JK: Stress free: To be or not to be? Anaesthesiology 1984; 61:643–4


45. Ray DC, McKeown DW: Effect of induction agent on vaso-


100. Unwin N: Refined structure of the nicotinic acetylcholine receptor at 4A resolution. J Mol Biol 2005; 346:967–89


104. Olsen RW, Sieghart W: GABA(A) receptors: Subtypes provide diversity of function and pharmacology. Neuropharmacology 2008; 56:141–8


120. Sanna E, Murgia A, Casula A, Biggio G: Differential subunit dependence of the actions of the general anaesthetics alphaxalolol and etomidate at gamma-aminobutyric acid type A receptors expressed in Xenopus laevis oocytes. Mol Pharmacol 1997; 51:848–90


140. Ahern GP: General anesthetics activate a nociceptive ion channel to enhance pain and inflammation. Proc Natl Acad Sci USA 2008; 105:8784–9


142. Ullerås E, Ohlsson A, Oskarsson A: Secretion of cortisol and aldosterone is strongly attenuated by GABA<sub>A</sub>-induced intersubunit conformational movement in the GABA<sub>A</sub> receptor. J Neurosci 2006; 26:3713–20

143. Reynolds DS, Rosahl TW, Reynolds DS, Newman RJ, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45


147. Christensen HD, Lee IS: Anesthetic potency and acute toxicity of optically active disubstituted barbituric acids. Toxicol In Vitro 1993; 58:64–8


149. Reynolds DS, Rosahl TW, Cirone J, O'Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

150. Reynolds DS, Rosahl TW, Cirone J, O'Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

151. Reynolds DS, Rosahl TW, Cirone J, O'Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

152. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

153. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

154. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

155. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

156. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

157. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

158. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

159. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45

160. Reynolds DS, Rosahl TW, Cirone J, O’Meara GF, Hurton W, Kafford A: γ-Aminobutyric acid type A receptor β2 subunit mediates the hypothalamic effect of etomidate in mice. Anesthesiology 2004; 100:1458–45